International Clinical Trial: Prospective proteogenomics-driven targeted therapy basket trial(no.3-1 gamma IFN subprotocol)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (KCT0012307) titled 'Prospective proteogenomics-driven targeted therapy basket trial(no.3-1 gamma IFN subprotocol)' on July 21.

Study Type: Interventional Study

Study Design: Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable

Primary Sponsor: Ajou University Hospital

Condition:

Neoplasms

Intervention: Drug : The planned dose of pembrolizumab in this clinical trial is 200 mg administered every 3 weeks for a maximum of 35 administrations. Pembrolizumab 200 mg will be administered as an intravenous infusion over 30 minutes. The infusion should be administered over approx...